5 days course about the drug development process and the ability to develop biologically active macromolecules



Traditionally it has been believed that the public sector – as the main steward of the health system – is responsible for driving access to medicines. However, COVID-19 pandemic has exposed vast inequities in access to medicines between countries. This has been especially evident for low and middle-income countries.
For the past two decades, the global health community has supported various investments, including public-private partnerships (PPPs), to accelerate access to medicines for LMICs through increasingly sophisticated mechanisms. New public, private and philanthropic resources have served as catalytic funding and these investments have yielded important results. It is important we learn from these various access to medicines initiatives and understand how countries can advance sustainable access to medicines – especially for non-communicable diseases NCDs in the context of Universal Health Coverage UHC.

During these two sessions, we will explore the following questions: What do we mean by market actors? What is the role of public-private partnerships in driving access to medicines in LMICs? What is the role of the public sector? Who pays for medicines and who delivers? What is the responsibility of consumers and patients?
After the sessions, you will have strengthened your capacity to understand and deal with crucial issues around access to medicines in LMICs. You will have learned about key trends in access to medicines in LMICs, the most recent trends, and innovations, and what this means for you as a market actor.

You will have:

  •  Acquired basic access to medicines in LMIC vocabulary,
    including innovative approaches.
  • Gained insight into the toolbox of access to medicines in
    LMICs and methodologies.
  • Obtained an overview of the key challenges of market access in LMICs.
  • Identified the key stakeholders and their influence on shaping access to medicines in LMICS.
  •  Gained an understanding of payer perspectives in fragmented LMIC markets.
  • Developed skills that will allow you to generate, apply and present evidence to maximize a strategy for access to medicine in LMICs.

Access to medicines is an essential part of achieving Universal Health Coverage (UHC) and the Sustainable Development Goals (SDGs).

The two sessions will provide you with insight into the key principles and a practical understanding of access to medicines in LMICs.

The topics include:

    • The importance of access to medicines in LMICs and an understanding of innovations – public-private partnerships – to drive access to medicines in LMICs. A series of short learning case studies on PPPs will be presented and the broad lessons from PPPs for sustainable access to medicines in LMICs will be drawn.
    • How global health organizations (World Health Organization) support access to medicines in LMICs. What is the role of the Essential Medicines List (EML) and how has it driven access to medicines in LMICs? What are the differences in access to medicines across different categories of diseases, e.g. communicable, non-communicable, neglected tropical diseases, COVID-19?
    • What is the role of health financing in driving access to medicines in LMICs? Who should pay for essential medicines? What is the role of public and private health insurance? Is there a role for out-of-pocket spending on medicines? Under what conditions?

Session 1:

    • Theme: Public-Private Partnerships for Access to Medicines in LMICs.

Session 2:

    • Introduction: Health and Access to Medicines (A2M) as a human right, relating to SDGs. Conceptual frameworks on A2M and A2M as ”complex systems”
    • A2M and research and development and linking research and practice through Health Technology Assessment (HTA)
    • Innovation and A2M: pharmaceutical development and access (market failures, state intervention and public research and development policies)
    • Issues around manufacturing and supply chain, the examples of anti-microbial resistance and CoViD
    • HTA
    • Role of community pharmacies and hospitals in appropriate access and public policies for UHC and A2M, with the example of the UK

The two sessions is for professionals working in the field of access to medicines in LMICs both public and private sector. This could include policymakers in Ministries of Health, non-governmental organizations (NGOs), patient organizations, and the private sector (pharmaceutical companies in LMICs or international pharma companies with a focus on LMICs).

Participants must:

    • Hold a relevant bachelor’s degree or equivalent
    • Have a minimum of 2 years of relevant job experience
    • Be proficient in English


About the sessions

”The sessions is
funded by EUs 4EU+ programme and is free of charge”

”The sessions is for
professionals working in the field of access to medicines in LMICs whether in the public or private sector”

Directors for session 1

Directors for session 2

Course information

Duration: Two online sessions in October (4 hours each, online).
Dates and time: October 7th and 14th, both days 10 am - 2 pm (including
lunch break)
Price: The sessions is funded by EUs 4EU+ programme and is free
of charge.
Language: English
Location: Online
Registration deadline: October 6, 2022
Contact: Thomas Stengade Sønderskov
+45 9356 56 97